Printer Friendly

Iterum Therapeutics initiates two Phase 3 clinical trials for sulopenem.

Iterum Therapeutics announced its initiation of the second and third of three planned Phase 3 clinical trials for sulopenem, Iterum's lead compound and novel antibiotic for the treatment of gram-negative, multi-drug resistant infections. In the second trial, known as sulopenem for resistant enterobacteriaceae, or SURE 2, IV sulopenem followed by oral sulopenem etzadroxil combined with probenecid in a bilayer tablet will be compared to IV ertapenem followed by oral ciprofloxacin in adults with complicated urinary tract infections. In the third trial, known as SURE 3, IV sulopenem followed by oral sulopenem is compared to IV ertapenem followed by a combination of oral ciprofloxacin and oral metronidazole in adults with complicated intra-abdominal infections.

COPYRIGHT 2018 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Sep 18, 2018
Words:112
Previous Article:Stephens highlights Red Robin, BJ's Restaurants as restaurant M&A candidates.
Next Article:GrubHub price target raised to $180 from $160 at Craig-Hallum.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |